Clinical trial

Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)

NCT03040791

Study summary

ClinicalTrials.gov

Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Nivolumab Normalized identity: nivolumab View linked drug · Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-06-01

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

NivolumabDRUG · verified · RxNorm: nivolumab

Sponsors & collaborators

Hospital Moinhos de Ventolead sponsor

Bristol-Myers Squibbcollaborator

Mapped research locations

São PauloSão Paulo, Brazil1 Porto AlegreRio Grande do Sul, Brazil1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03040791 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.